Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · IEX Real-Time Price · USD
27.77
-0.73 (-2.56%)
Mar 28, 2024, 2:41 PM EDT - Market open

Aerovate Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year 20232022202120202019
Cash & Equivalents
23.4922.454.24.573.51
Short-Term Investments
98.95106.82113.1800
Cash & Cash Equivalents
122.44129.22167.384.573.51
Cash Growth
-5.25%-22.80%3560.07%30.14%-
Other Current Assets
1.792.286.960.10
Total Current Assets
124.23131.5174.334.683.51
Property, Plant & Equipment
0.91.250.730.040
Other Long-Term Assets
2.282.560.300
Total Long-Term Assets
3.193.811.030.040
Total Assets
127.42135.3175.364.723.51
Accounts Payable
2.42.581.210.620.54
Current Debt
0.420.390.1900
Other Current Liabilities
14.824.821.151.160.12
Total Current Liabilities
17.647.782.551.770.66
Long-Term Debt
0.260.710.3802.5
Other Long-Term Liabilities
0.070.070.0104
Total Long-Term Liabilities
0.330.780.406.5
Total Liabilities
17.968.562.951.777.16
Total Debt
0.681.090.5702.5
Debt Growth
-38.07%89.90%---
Retained Earnings
-163.42-87.9-36.39-13.41-3.64
Comprehensive Income
0.24-0.47-0.0600
Shareholders' Equity
109.46126.74172.42-13.34-3.64
Net Cash / Debt
121.76128.13166.84.571.01
Net Cash / Debt Growth
-4.97%-23.18%3547.52%350.99%-
Net Cash Per Share
4.625.2413.5718.881.35
Working Capital
106.6123.71171.782.92.86
Book Value Per Share
4.165.1814.03-55.09-4.86
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).